Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW +5.36%80 Days Payable is 117.76 as of Jun. 2026, which is 8% below its 10-year median of 128.61. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 924 Drug Manufacturers companies, Harrow ranks better than 68.83% on this metric.
Harrow's average Accounts Payable for the
three
months ended in Jun. 2026 was $26.2 Mil. Harrow's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $20.3 Mil.
Hence, Harrow's Days Payable for the
three
months ended in Jun. 2026 was 117.76.
The historical rank and industry rank for Harrow's Days Payable or its related term are showing as below:
HROW'
s Days Payable Range Over the Past 10 Years
Min: 83.5 Med: 128.61 Max: 223.05
Current: 129.03
During the past 13 years, Harrow's highest Days Payable was 223.05. The lowest was 83.50. And the median was 128.61.
HROW's Days Payable is ranked better than 68.83% of 924
companies
in the Drug Manufacturers industry
Industry Median: 88.695
vs HROW: 129.03
Harrow's Days Payable
declined
from Jun. 2025 (170.10) to Jun. 2026 (117.76).
It may suggest that Harrowaccelerated paying its suppliers.
The historical data trend for Harrow's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's Days Payable distribution charts can be found below:
* The bar in red indicates where Harrow's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Harrow's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow (HROW) has a Days Payable of 117.76 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harrow and its competitors. This is near median its historical median of 128.61. Over the past decade, Harrow's Days Payable has ranged from 83.50 to 223.05. According to the industry distribution chart, Harrow ranks #288 out of 924 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Harrow's Days Payable too high?
Harrow's current Days Payable of 117.76 is near median its 10-year median of 128.61. Over the past 10 years, this metric has ranged from a low of 83.50 to a high of 223.05. The Drug Manufacturers industry median Days Payable is 88.70. Harrow's value of 117.76 is 32.8% above this industry median. Based on the distribution chart, Harrow ranks #288 out of 924 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's Days Payable compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #288 out of 924 companies for Days Payable. This puts Harrow in the upper half of its industry. The industry median Days Payable is 88.70. Harrow's value of 117.76 is 32.8% above this benchmark. Historically, Harrow's own Days Payable has ranged from 83.50 to 223.05 over the past decade. While the company's 10-year median is 128.61 vs. the industry median of 88.70, Harrow has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.70, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harrow's current Days Payable of 117.76 is 32.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current Days Payable is 117.76, which is near median its own 10-year median of 128.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.63 — trading 0.9% below its estimated fair value. The current Days Payable is 117.76, which is near median its 10-year median of 128.61 and 32.8% above the Drug Manufacturers industry median of 88.70. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Harrow (HROW), the current Days Payable is 117.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.63 is trading 0.9% below its estimated GF Value™ of $42.00.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
Days Payable: 117.76 (near median its 10-year median of 128.61)
GF Value™: $42.00 vs. price of $41.63 (0.9% below fair value)
Industry Position: 32.8% above the Drug Manufacturers median (#288 of 924)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score
Get the complete analysis for HROW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
